Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDO1 short hairpin RNA (IDO1 shRNA) is an experimental RNA interference (RNAi) therapeutic designed to silence the expression of indoleamine 2,3-dioxygenase 1 (IDO1). IDO1 is a rate-limiting enzyme in the tryptophan catabolism pathway that facilitates immune evasion by depleting tryptophan and producing kynurenine in the tumor microenvironment. By knocking down IDO1 expression, this shRNA modality aims to restore antitumor immunity, enhance neutrophil infiltration, and increase interferon-gamma levels. Preclinical studies have explored its use in various malignancies, including ovarian, bladder, and lung cancers, often delivered via plasmid or viral vectors to sensitize tumors to chemotherapy or enhance immune-mediated tumor suppression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ido1 short hairpin rna.